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Impaired transmission in GABAergic circuits is thought to contribute to the pathogenesis of epilepsy. Although
it is well established that major reorganization of GABAA receptor subtypes occurs in the hippocampus of
patients with medically refractory temporal lobe epilepsy (TLE), it is unclear whether this disorder is also
associated with alterations in GABAA receptor subtypes in the neocortex. Here we have investigated immuno-
histochemically the subunit composition and neocortical distribution of threemajor GABAA receptor subtypes
using antibodies specifically recognizing the subunits a1, a2, a3, b2/3 and g2. Cortical tissue was obtained at
surgery from patients with TLE and hippocampal sclerosis (HS; n = 9), TLE associated with neocortical lesions
(non-HS; n = 12) and frontal lobe epilepsy (FLE; n = 5), with post-mortem samples serving as controls (n = 4).
A distinct laminar and neuronal expression pattern of the a-subunit variants was found across the neocortical
regions examined in the temporal and frontal lobes in both control and patient tissue samples. In the five
patients with FLE, GABAA receptor subunit staining was unchanged as compared to controls. In patients with
TLE we observed a marked decrease in a3-subunit staining in the superficial neocortical layers (I–III), but no
change in the deep layers (V and VI) or in the expression pattern of the a1 and a2-subunits. Reduced expression
in a3-containing GABAA receptors was detected in six out of nine patients of the HS group and four out of
twelve patients of the non-HS group. Histopathological changes were present in eight out of the ten patients
with decreased a3-subunit staining. The selective reduction in a3-containing GABAA receptors was confirmed
using semiquantitative measurements of optical density (OD). The specific changes unique to a3-subunit
expression in the superficial neocortical layers of patients with TLE suggest that this subtype is of particular
significance in the reorganization of cortical GABAergic systems in focal epilepsy.
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Abbreviations: ECoG ¼ electrocorticography; FLE ¼ frontal lobe epilepsy; HS ¼ hippocampal sclerosis;
OD ¼ optical density; TLE ¼ temporal lobe epilepsy
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Introduction
A variety of evidence indicates that inhibitory brain circuits,
which depend primarily on signalling through GABAA
receptors, are functionally impaired in epilepsy. Thus,
blocking GABAA receptors pharmacologically promotes the
generation of seizures in animals and in humans, whereas
drugs that enhance GABAA receptor function are effective in
treating seizures. This straightforward notion becomes more
complex, however, when taking into account the wide array
# The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
of structurally and functionally distinct GABAA receptor
subtypes found in the central nervous system. Nineteen
GABAA receptor subunits (a1–6, b1–3, g1–3, d, «, p, ,
r1–3) have been identified and cloned from the mammalian
CNS (Simon et al., 2004), which theoretically can assemble
into a vast number of distinct pentameric receptors. In fact,
only a few dozen of these potential combinations are found
in the brain, most of which include at least one of each of
the a, b and g subunit class (Fritschy and Mo¨hler, 1995;
Pirker et al., 2000). Furthermore, these distinct receptor
subtypes are preferentially expressed in specific regions and
neuronal populations and they exhibit different sensitivities
to modulators including neurosteroids, benzodiazepines,
ethanol and barbiturates (Sieghart and Sperk, 2002; Fritschy
and Bru¨nig, 2003).
Temporal lobe epilepsy (TLE) is the most common form
of focal epilepsy in adults, and, when associated with
hippocampal sclerosis (HS), is the most refractory to
pharmacotherapy (Wieser and ILAE Commission on
Neurosurgery of Epilepsy, 2004). Although abundant
human data are available regarding reorganization of
GABAergic interneuron circuits in the neocortex and
hippocampus of TLE patients (DeFelipe, 1999; Sperk
et al., 2004; Maglo´czky and Freund, 2005), most studies
aimed at characterizing the alterations of individual
GABAA receptor subtypes in human TLE have focused on
the hippocampus (Brooks-Kayal et al., 1999; Loup et al.,
2000; Pirker et al., 2003; Porter et al., 2005). Previous
immunohistochemical investigations of GABAA receptors in
the neocortex of patients with refractory focal epilepsy
were restricted to the a1-subunit (Wolf et al., 1994,
1996b). Results from autoradiographic investigations in the
neocortex of patients with pharmacoresistant epilepsy
yielded divergent conclusions, reporting no changes,
decreases or increases in GABAA receptors (Olsen et al.,
1992; Burdette et al., 1995; Nagy et al., 1999; Zilles et al.,
1999; Sata et al., 2002). In vivo imaging studies using 11C-
flumazenil, an antagonist at the benzodiazepine–GABAA
receptor complex, have shown both focal increases and
decreases of flumazenil binding in the neocortex of patients
with partial epilepsy (Theodore, 2002; Koepp and
Woermann, 2005). Although flumazenil-PET studies are
indispensable for tracking changes in living subjects, the
resulting images provide low spatial resolution of GABAA
receptor distribution and flumazenil fails to distinguish
between the different GABAA receptor subtypes. In the
present study, we have used an immunohistochemical
approach to investigate alterations in GABAA receptor
subtype organization in neocortex removed at surgery from
patients with medically intractable focal epilepsy. Tissue was
processed following a protocol based on microwave
irradiation to visualize the major GABAA receptor subunits
a1, a2, a3, b2/3 and g2 with subunit-specific antisera (Loup
et al., 1998). Other potentially relevant subunits could not
be studied as the corresponding antisera effective in human
brain tissue are not yet available.
Material and methods
Patient selection, intraoperative
electrocorticography
Twenty-six patients undergoing surgery for medically intractable
focal epilepsy were included in this study. Brain tissue was obtained
from the neurosurgical units of the University Hospitals of Zurich,
Geneva and Strasbourg. All procedures were performed with the
informed consent of the patients or legal next of kin and were
approved by the ethics committees of the respective institutions
according to the Declaration of Helsinki. Presurgical assessment
comprised high-resolution MRI, PET with 18fluoro-2-deoxyglucose
and/or ictal and interictal single photon emission computed
tomography for all cases, functional MRI in six cases, and magnetic
resonance spectroscopy (MRS) in five cases. All patients underwent
scalp EEG and, where indicated, invasive or semi-invasive EEG
recordings were obtained (Zumsteg and Wieser, 2000). Based on
the histopathological findings in conjunction with neuroimaging,
EEG and clinical data, patients were categorized into those with
frontal lobe epilepsy (FLE) (n = 5, mean age at surgery 6 SD:
22.6 6 12.3 years, range 5–34 years) and those with TLE. The latter
group was further subdivided into those with HS (n = 9, mean age
at surgery 6 SD: 39.6 6 14.4 years, range 12–56 years) and those
with neocortical lesions (non-HS; n = 12, mean age at surgery 6
SD: 28.3 6 12.2 years, range 9–49 years). Patients with focal
cortical dysplasia (FCD) alone were specifically excluded. Relevant
clinical data are summarized in Table 1.
Intraoperative electrocorticography (ECoG) was performed in 18
of 26 patients with grids of 4 · 8 electrodes and/or with strips of
four electrodes (Pt/Ir) embedded in Silastic sheets (Ad-Tech,
Racine, WI). In FLE patients, electrodes were placed over the
exposed prefrontal and polar cortex and positioning of the grid and
strip electrodes was modified to record from neighbouring areas
where indicated. In TLE patients, the 4 · 8 grid was placed over the
anterior and middle temporal lateral and inferior cortex and the
strip electrode was positioned on the intraventricular hippocampus
allowing for simultaneous recording from lateral and inferior
temporal neocortex and from hippocampus. Centre-to-centre
inter-electrode distance was 1 cm, the diameter of each electrode
was 1.2 mm. Recordings were sampled at 400 Hz, with a bandwidth
of 1–70 Hz over a minimum period of 25 min, using a 32-channel
Nihon-Kohden EEG system. Spiking areas were defined where
electrodes showed spikes and/or sharp waves with a mean
frequency greater than 1 spike/min (+, 1–10; ++, 11–20; +++,
> 20 spikes/min). Non-spiking areas were defined where electrodes
showed no epileptiform graphoelements. Degree of spiking (+, ++,
+++) was taken into account, as well as propagation if present.
ECoG was carried out before resection and repeated during the
surgical procedure as necessary. After surgical ablation, ECoG was
performed again and showed either spike-free activity or residual
spiking at the resection border. Residual spiking was anatomically
localized and its degree was rated (+, ++, +++).
All tissue blocks were from resections performed for strictly
therapeutic purposes. The surgical procedures included corticect-
omy or lesionectomy in the frontal or temporal lobe or anterior
temporal lobectomy. Sixteen patients underwent amygdalo-
hippocampectomy and HS was confirmed histopathologically in
nine of these cases. The neocortical tissue samples originated from
the anterolateral temporal neocortex and the frontopolar area, the
frontal lateral region, and the orbital part of the inferior gyrus of
the frontal lobe. In the patients with a circumscribed pathology,
neocortical samples were collected within and adjacent to the
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lesion. Finally, control neocortical tissue from four subjects (mean
age 6 SD: 62.5 6 11.1 years, range 48–73 years) with no known
history of neurological or psychiatric disorders was collected at
autopsy (mean post-mortem interval 6 SD: 11.2 6 3.4 h). Results
on the hippocampi of these four subjects were reported in a
previous study (Loup et al., 2000). The left, and, in two cases, also
the right hemispheres were cut into coronal slabs of 1–1.5 cm
thickness. One to three tissue blocks per subject were dissected
from parts of the anterolateral temporal neocortex, which
corresponded to the areas removed in those patients undergoing
surgery for epilepsy. In one case, three blocks of control tissue were
also dissected from the frontal lobe.
Tissue preparation
Immediately upon resection in the operating room or after
dissection at autopsy, tissue blocks were rinsed in phosphate-
buffered saline (PBS) at pH 7.4. They were then immersion-fixed
for 6–8 h at 4C under constant agitation in a mixture of 4%
freshly dissolved paraformaldehyde and 15% saturated picric acid
in 0.15 M phosphate buffer at pH 7.4 (Somogyi and Takagi, 1982)
or in 4% paraformaldehyde alone. Following fixation, tissue blocks
were pre-treated using a modified antigen-retrieval method based
on microwave irradiation as described previously (Loup et al.,
1998). Tissue blocks were cryoprotected in 10, 20 and 30% sucrose
in PBS over a period of 3–4 days, frozen at 28C in isopentane,
and stored at 80C. Series of 40 mm thick sections were
subsequently cut in a cryostat and collected in ice-cold PBS. These
were either processed for immunohistochemistry (see below) or
transferred to antifreeze solution and stored at 20C until use.
This procedure allowed up to 12 different specimens to be
processed in parallel. Staining for each of the five GABAA receptor
subunits was always carried out on five consecutive sections with an
interseries space of 720–800 mm. For histopathological examina-
tion, two additional adjacent series of sections were stained for
Nissl with cresyl violet and with antibodies against the neuron-
specific nuclear protein NeuN (Wolf et al., 1996a). In selected cases,
we also used antibodies against glial fibrillary acid protein (GFAP)
and an antiserum that recognizes specifically a non-phosphorylated
epitope of neurofilament protein (SMI-32) and labels a subpopula-
tion of pyramidal cells (Campbell and Morrison, 1989).
Immunohistochemistry
The following subunit-specific antibodies were used: mouse
monoclonal antibodies bd-24 and bd-17 recognizing the human
GABAA receptor a1-subunit and both the b2 and b3-subunits,
respectively (Schoch et al., 1985; Ewert et al., 1990), and polyclonal
guinea-pig antisera recognizing the a2, a3 and g2-subunits. The
specificity of these antibodies has been extensively documented
(Fritschy and Mo¨hler, 1995; Loup et al., 1998; Waldvogel et al.,
1999). The dilutions of the subunit-specific antibodies were:
a1-subunit (monoclonal antibody bd-24), 0.14 mg/ml; a2-subunit
(affinity-purified), 1.3 mg/ml; a3-subunit (crude serum), 1:3000;
b2/3-subunit (monoclonal antibody bd-17), 3.8 mg/ml; and
g2-subunit (crude serum), 1:1500. Further, antibodies used were
NeuN 1:1000 (MAB377; Chemicon, Temecula, CA), GFAP
1:100 000 (MAB360, Chemicon, Temecula, CA), and SMI-32
1:5000 (Sternberger Monoclonals Inc.; Covance Research Products,
Berkeley, CA). Series of free-floating sections were pre-incubated in
1.5% H2O2 in PBS for 10 min at room temperature to block
endogenous peroxidase activity. They were then washed three times
for 10 min in PBS and processed for immunoperoxidase staining
(Hsu et al., 1981) as described previously (Loup et al., 1998, 2000).
Data analysis
Sections were analysed with a Zeiss Axioskop 2 (Jena, Germany)
equipped for bright-field microscopy. For display, images
were digitized using a high-resolution camera (AxioCam; Zeiss,
Jena, Germany) with Zeiss camera software (AxioVision version
4.4). Images were modified for contrast only and comparison
images were adjusted uniformly (Adobe Photoshop version 7.0;
Adobe Systems Incorporated, San Jose´, CA). No other manipula-
tion of images was performed. Illustrations were composed
in Adobe Illustrator (version 10.0; Adobe Systems Incorporated,
San Jose´, CA).
Densitometric measurements
The intensity of labelling for the GABAA receptor subunits a1, a2,
and a3 was measured by densitometry in sections from controls
(n = 4), FLE (n = 4), HS (n = 8), and non-HS cases (n = 10) as
described previously (Loup et al., 2000). Optical density (OD)
measurements were recorded in the superficial (layers II and III)
and deep layers (layers V and VI) of the neocortex. The average OD
per section was calculated from measurements in four rectangles
with an area of 400 · 200 mm each in the superficial as well as in
the deep layers and all measurements were repeated twice in sets of
adjacent sections for each patient. In four patients, insufficient
tissue was available to perform a complete quantitative analysis of
the subunits.
Statistical analysis
Densitometric measurements were analysed for statistical signifi-
cance using the Kruskal–Wallis test [non-parametric analysis of
variance (ANOVA); GraphPad Prism, GraphPad Software, San
Diego, CA]. Data were further compared between individual
groups (at P < 0.05) with a multiple comparisons test. In the cases
where more than one block was available, values were first
subjected to statistical analysis to ensure that interblock variations
were not significant.
Results
The distribution of the GABAA receptor subunits a1, a2, a3,
b2/3 and g2 was analysed in neocortical specimens from
three different groups of patients with medically intractable
focal epilepsy. Tissue obtained at autopsy from patients with
no evidence of neurological disease was used for controls as
previous data indicated that staining patterns for GABAA
receptor subunits in autopsy and surgical samples are
comparable (Loup et al., 2000).
Patient histories and histopathological
evaluation
Table 1 provides a summary of the relevant clinical data for
each patient. The duration of epilepsy ranged from 4 to 29
years in the FLE group, from 10 to 44 years in the HS group
and from 1 to 32 years in the non-HS group. Mean epilepsy
duration was 13.4 years in the FLE group, 30.7 years in the
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HS group and 10.6 years in the non-HS group. The mean
age of onset was 9.2 years in the FLE group, 8.9 years in the
HS group and 17.6 years in the non-HS group. In the HS
group, but not in the FLE or non-HS groups, an initial
precipitating event was documented as described previously
(French et al., 1993; Mathern et al., 1995), including febrile
convulsions (n = 4), infantile meningitis/encephalitis (n = 2)
and neonatal anoxia/ischaemia (n = 1). The overall mean
postsurgical follow-up period was 57.3 months. Seizure-free
status (class I; Engel, 1987) was achieved for all patients of
the HS group, 9 out of 12 patients in the non-HS group and
1 patient of the FLE group.
With respect to the patients with FLE, histopathological
examination revealed discrete focal Chaslin’s subpial gliosis
(n = 1), leptomeningeal venous angiitis with no abnorm-
alities in the brain parenchyma (n = 1), a low grade tumour
(n = 1), and a glial scar (n = 2). In the patients with
histopathologically confirmed HS, examination of the
anterolateral temporal neocortex showed mild Chaslin’s
subpial gliosis (n = 3), gliosis (n = 4) and/or white matter
changes. Thus, in two cases, small aggregates of heterotopic
neurons were detected in the subcortical white matter.
According to Palmini et al. (2004), such abnormalities are
classified as type II mild malformations of cortical
development (mild MCD II). In contrast, in neocortical
grey matter, staining for Nissl, NeuN or SMI-32 revealed a
normal cytoarchitecture with no apparent neuronal cell loss
(see Fig. 4A and D). The non-HS group consisted of patients
with vascular cavernous malformations (n = 3), low grade
tumours (n = 8) and a glial scar secondary to cranial trauma
(n = 1). All lesions were located in the anterolateral temporal
neocortex. In 4 of the 12 patients with non-HS we also
found histopathological changes in tissue adjacent to the
lesion. In particular, dyslamination and large neurons were
observed in two cases, one with a dysembryoplastic
neuroepithelial tumour (DNT) and the other with a
ganglioglioma. According to Palmini et al. (2004), the
abnormalities described above are consistent with type IB
(FCD IB). Neocortical tissue from autopsy controls
displayed a normal cytoarchitecture.
GABAA receptor subtypes in control
grey matter
We first examined the distribution of the GABAA receptor
subunits a1, a2, a3, b2/3 and g2 in temporal neocortex at
low power magnification (Fig. 1). Adjacent sections were
stained for the neuronal marker NeuN to identify laminar
borders. All subunit antibodies revealed specific patterns of
immunoreactivity. In normal grey matter, the laminar
pattern for the subunits a1, a2 and a3 was distinct, whereas
the laminar pattern was similar for the subunits b2/3 and g2
(Fig. 1). A comparable organization was also described in
rodent brain where the a-subunit variants represent largely
distinct subtypes with a specific pharmacological profile
while the b2/3 and g2-subunits are common to most
GABAA receptor subtypes (Fritschy and Mo¨hler, 1995).
Furthermore, the distribution pattern for the a1-subunit
was nearly identical to that of the b2/3 and g2-subunits,
indicating that the a1-subunit is the most abundant of the
a-subunit variants in the human neocortex. Unless
otherwise mentioned, the ubiquitously present subunits
b2/3 and g2, although analysed, will not be further
described.
Figure 2 shows at higher magnification the distinct and
specific pattern of laminar distribution in neocortex of each
of the a-subunit variants tested. Staining for the a1-subunit
was particularly intense in the lower part of layer III and in
layer IV (Fig. 2B). A weaker labelled band corresponding
to the upper/mid layer IV in adjacent NeuN and SMI-32-
stained sections was often observed (Fig. 2A and B) and was
best seen at low power magnification (Fig. 1). For the
a2-subunit, labelling was pronounced in the superficial layers
and weak in the deep layers (Figs. 1 and 2C). A transition in
labelling intensity generally was apparent in layer IV.
Immunoreactivity for the a3-subunit was most intense in
layer II and the upper part of layer III, gradually decreasing
Fig. 1 Regional distribution of the major GABAA receptor
subunits in temporal neocortical tissue obtained at autopsy
from a control. Adjacent sections were stained for the subunits
a1, a2, a3, b2/3 and g2, and for NeuN. The NeuN staining
illustrates the laminar distribution of neuronal cell somata. Each
of the a-subunit variants exhibits a distinct laminar distribution
whereas labelling for the b2/3 and g2-subunits is largely similar.
Note that the a1-subunit has a nearly identical distribution
pattern to that of the b2/3 and g2-subunits. Scale bar: 2 mm.
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toward the lower part of layer III. Layer IV was only
lightly labelled (Figs. 1 and 2D). The deep layers were
moderately labelled. Even at this power of magnification,
apical dendrites originating from layers V and VI could be
seen to extend toward the pial surface (Fig. 2D). For each
subunit, similar patterns of staining were observed in
temporal and frontal neocortical tissue of all autopsy cases
(data not shown).
At the cellular level, staining for the a2-subunit was
present in the neuropil of each layer with the neuronal cell
bodies appearing lightly labelled against the background
(Fig. 3A). a3-Subunit immunoreactivity was also observed
in the neuropil, but additionally in the soma and dendrites
of individual neurons, including in pyramidal cells
predominantly situated in the lower part of layer III
(Fig. 3B). In layers V and VI, a subpopulation of neurons
was labelled that displayed the typical morphology of
pyramidal cells with a few basal dendrites and long apical
dendrites coursing toward the superficial layers (Fig. 3C).
Figure 3D shows a high magnification image of a layer V
pyramidal cell immunoreactive for the a3-subunit. For both
the a2 and a3-subunits, intense immunoreactivity was also
detected on the axon initial segment of pyramidal cells, as
shown previously (Loup et al., 1998). Staining for the a1-
subunit, and less prominently for the b2/3 and g2-subunits,
was not only seen in the neuropil, but also in numerous
non-pyramidal cells. In particular layer II and the upper part
of layer III displayed a high density of intensely stained
interneurons with somata of small size and several, often
radially oriented, dendrites (Fig. 3E).
GABAA receptor subtypes in the grey
matter of patients with focal epilepsy
Neocortical tissue from patients with FLE, HS or non-HS
was analysed for changes in GABAA receptor subunit
immunoreactivity. In the patients with a circumscribed
lesion in the neocortex (see Table 1), the tissue samples used
for study were from the periphery of the lesion. Two major
observations were made. First, in all three groups the
staining pattern for the subunits a1 and a2, as well as b2/3
and g2, was largely similar to that of controls in terms of
laminar distribution and intensity (Fig. 4B, C and E).
Secondly, a subset of patients (10/26) was found to exhibit
markedly decreased a3-subunit staining in the superficial
layers, whereas the deep layers appeared unchanged and thus
provided an internal control within each section for each
case (Figs. 4F and 5). In the patients with reduced a3-
subunit staining, no apparent neuronal cell loss was
observed in adjacent sections stained for SMI-32 or NeuN
(Fig. 4A and D). The data for the a3-subunit in the
superficial neocortical layers for each patient are summar-
ized in Table 1.
In the group of patients with FLE (n = 5), no changes
in a3-subunit immunoreactivity were observed as com-
pared to controls. In the HS group (n = 9), a3-subunit
Fig. 2 Differential laminar distribution of GABAA receptor subunit immunoreactivity in control human temporal cortex. (A) NeuN-stained
section. The characteristic six-layered structure of neocortex (I–VI) was used to define the laminar borders in adjacent immunostained
sections. (B) a1-Subunit immunoreactivity is present throughout the six layers, but most intense in the lower part of layer III and IV. A
lighter band of staining beneath layer III corresponds to the upper/mid part of layer IV. Note the staining of the neuropil, in which individual
neurons cannot be distinguished at this magnification. (C) a2-subunit immunoreactivity is most abundant in the superficial layers (I–III),
decreases progressively (III and IV) and becomes weakest in layers V and VI. (D) a3-Subunit immunoreactivity is most intense in layer II
and the upper part of layer III, light in layer IV and moderate in layers V and VI. Labelled apical dendrites originating from layer V and VI
pyramidal cells and extending towards the superficial layers (arrows) are observed even at this low magnification. Scale bar: 400 mm.
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immunoreactivity was unchanged in three and decreased in
five cases. In the remaining case, regions of unchanged and
decreased a3-subunit staining were seen in the superficial
layers in two different samples while no alterations were
observed in a3-subunit staining in the deep layers. In the
non-HS group (n = 12), a3-subunit labelling was unchanged
in seven cases, decreased in the superficial layers in four
cases, and could not be determined in one case. Fig. 5 shows
low power images of the laminar distribution pattern of the
a3-subunit from six different cases (five HS, one non-HS),
three of which had no changes and three of which had
decreased a3-subunit staining in the superficial neocortical
layers.
Semiquantitative densitometric analysis was performed to
assess differences in staining intensity between the control,
FLE, HS and non-HS groups for the subunits a1, a2 and a3
in the superficial and the deep layers of temporal or frontal
neocortical tissue (Fig. 6). The following observations were
made: (i) no significant differences in OD were found for the
a1 and a2-subunits in the superficial or the deep layers
between the different groups of patients (Fig. 6A–D). (ii)
Differences in OD for the a3-subunit were observed in the
superficial layers of a subset of patients in both the HS and
the non-HS groups (Fig. 6E). When compared to the FLE
group, a3-subunit OD was significantly decreased in both
the HS and the non-HS groups (P < 0.01 and P < 0.05,
Fig. 3 Differential cellular distribution of GABAA receptor subunit immunoreactivity in control human temporal neocortex.
(A) a2-Subunit staining in the neuropil. The lightly labelled round structures represent pyramidal cell somata located in layer II. (B–D)
a3-Subunit immunoreactivity. In B, a pyramidal cell in the lower part of layer III exhibits strong staining of the soma membrane and long
dendrites whereas the surrounding neuropil is weakly stained. (C) Several layer V pyramidal cells with basal (arrows) and long apical
dendrites that extend throughout layer IV toward the pial surface. (D) High magnification of a layer V pyramidal cell with one apical and
several basal dendrites against the diffusely stained background. (E) a1-Subunit immunoreactivity. Prominent labelling against the diffusely
stained neuropil of two small interneurons (arrowheads), one of which displays radial dendrites. The large and lightly labelled structures
represent pyramidal cell somata. Scale bar: (A and B) 50 mm; (C) 100 mm; (D and E) 20 mm.
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respectively). Comparison within the HS group and within
the non-HS group showed that a3-subunit OD was
significantly decreased in a subset of patients (P < 0.0001
and P < 0.0001, respectively). (iii) No significant difference
in OD was found for the a3-subunit in the deep layers for all
patients (Fig. 6F).
At the cellular level, sections stained for the subunits a1
and a2 revealed similar patterns in all specimens when
compared to controls (data not shown). For the a3-
subunit, Fig. 7A shows a section from a case with an
unchanged pattern of staining similar to what was seen in
control tissue. In the HS and non-HS patients with changes
in a3-subunit immunoreactivity in the superficial neocor-
tical layers, a striking decrease in staining was present
throughout layers I, II and III (Fig. 7B–D). Moreover, in
layer II only, we observed pyramidal cells immunopositive
for the a3-subunit, which had apical dendrites extending
into layer I (Fig. 7C and D). These neurons possessed
numerous long dendrites, which at times formed an intri-
cate predominantly horizontal network with neighbouring
layer II neurons (Fig. 7C). Some cells had a prominently
labelled soma (Fig. 7D). Changes at the cellular level as
depicted in Fig. 7 were seen to a variable degree in the
temporal neocortex of all patients with reduced a3-subunit
staining.
Intraoperative ECoG, changes in
a3-containing GABAA receptors
and histopathology
ECoG was performed during surgery in 18 of 26 patients and
results were analysed in a semiquantitative manner as
described in Material and methods. As can be seen in Table 1,
no consistent correlation was found between the degree of
spiking activity recorded before resection and the changes in
a3-subunit staining or the histopathology. In particular,
areas with high spiking activity (+++) exhibited either
unchanged or decreased a3-subunit expression. The post-
resection ECoG recordings showed that no or only little
residual spiking was present at the border of the resection
except in one FLE patient with rhythmic discharges in the
contralateral frontal neocortex.
Fig. 4 Subunit-specific changes in GABAA receptor immunoreactivity in the temporal neocortex from two TLE patients. (A–C) Adjacent
sections stained for SMI-32 (A), the a1-subunit (B) and the a2-subunit (C). The distribution pattern of these subunits is unchanged as
compared to controls (see Figs. 1 and 2). (D–F) Adjacent sections stained for NeuN (D), the a2-subunit (E) and the a3-subunit (F).
The cytoarchitecture is conserved with no apparent neuronal cell loss. Note that layer-specific changes occur only for the a3-subunit, which
is decreased in the superficial layers and unchanged in the deep layers. Scale bar: (A–C) 300 mm; (D–F) 1 mm.
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Discussion
Our first principal finding is that in the normal human
neocortex the expression of five of the major GABAA
receptor subunits (a1, a2, a3, b2/3 and g2) displayed
remarkable laminar and neuronal specificity. Moreover,
the regional distribution of the GABAA receptor subunits
was similar across all the neocortical regions examined in
the temporal and frontal lobes. Second, in a subset of
patients with TLE we observed a decrease in a3-subunit
staining in the superficial neocortical layers, usually
accompanied by histopathological changes. In contrast, the
distribution and the intensity of labelling of the subunits a1,
a2, b2/3 and g2 were unchanged in patients with focal
epilepsy.
Methodological considerations
The feasibility of this study depended on the utilization of
high affinity antibodies and the quality and processing of the
tissue. We verified the specificity of the subunit-specific
antisera in human brain tissue in previous studies with
competition experiments, by replacing primary antibodies
with non-immune serum and in western blots (Loup et al.,
1998; Waldvogel et al., 1999). Moreover, to achieve high
specificity of staining with a low background, we used an
antigen-retrieval microwave procedure adapted to human
brain tissue (Loup et al., 1998).
A number of potential pitfalls must be considered in the
interpretation of our findings. (i) Variability, because tissue
samples originated from different epilepsy centres. However,
tissue processing was performed according to a common
protocol (Loup et al., 1998, 2000) and the specific reduction
in a3-subunit staining was found in tissue samples from all
three centres. (ii) A sampling problem, in that areas
compared between different patients were in fact not
homologous. This is rather unlikely as the location of the
resected neocortical areas was carefully documented and the
distribution of the subunits a1 and a2, which served as a
reference, was unchanged across samples. (iii) Effects of
confounding biographical/clinical data, in particular differ-
ences in pharmacotherapy or the occurrence of presurgical
seizures (Bouvard et al., 2005). Thorough review of the
clinical data from each patient failed to identify major
discrepancies among patients. Furthermore, it is unlikely
that the changes in a3-subunit expression are secondary to
drug treatment for the following reasons: a decrease in a3-
subunit expression was observed in tissue both from patients
taking GABAergic drugs and from patients not taking
GABAergic drugs. In other words, there was no correlation.
Also, at least four patients who were not treated with
GABAergic drugs at the time of surgery and with no history
of prior exposure nevertheless exhibited decreased a3-
subunit staining. Moreover, in patients in whom a3-subunit
expression was decreased in temporal neocortex, the
expression in the entorhinal cortex was unchanged
(F. Loup, unpublished data), whereas all five subunits
studied including the a3-subunit were differentially altered
in the hippocampus (Loup et al., 2000). (iv) Staining
artefacts. This possibility can be ruled out based on our
uniform processing in parallel of the various tissue samples.
In addition, immunohistochemical staining in the cases with
decreased a3-subunit labeling was repeated several times
and, finally, staining in the deep layers was unchanged, thus
providing an intrasection control.
GABAA receptor subtype expression in
normal grey matter
Among the three GABAA receptor subtypes identified in our
study, the a1-subtype was most abundant, with highest
staining in lower layer III and layer IV, followed by the a2
and the a3-subtypes. This is in line with the results of previous
autoradiographic GABAA receptor binding studies (Young
and Kuhar, 1979; Zezula et al., 1988) reporting high densities
of benzodiazepine receptor sites, especially in layers III
and IV. Using in situ hybridization for six GABAA receptor
subunit mRNAs (a1, a2, a5, b1, b2 and g2), Akbarian et al.
(1995) found three principal patterns of laminar expression in
normal human prefrontal cortex, with the a1-subtype
dominating. The laminar distribution pattern that they
reported for the a1, a2, b2 and g2-subunit mRNAs is largely
Fig. 5 GABAA receptor a3-subunit immunoreactivity in the
temporal neocortex from six TLE patients. The colour-coding
indicates OD of staining using a normalized scale with the
strongest signal in white and no signal (background) in dark
blue. (A, C and E) a3-subunit immunoreactivity in three patients
with HS showing no change in the laminar distribution of this
subunit. (B, D and F) In two other patients with HS (B and D)
and one with non-HS (F), staining for the a3-subunit is
decreased in the superficial layers and unchanged in the deep
layers. Scale bar: 1 mm.
Cortical GABAA receptors in human epilepsy Brain (2006), 129, 3277–3289 3285
similar to that described in the present immunohistochemical
study. Moreover, the GABAA receptor subunits a1, b2/3 and
g2 show a similar laminar distribution in the human visual
cortex with immunoreactivity greatest in layer IV (Hendry
et al., 1994). Finally, electrophysiological data from a study in
human temporal cortical neurons demonstrated a benzodia-
zepine sensitivity profile consistent with a preponderance of
a1-subunit expression (Gibbs et al., 1996).
Fig. 6 Densitometric measurements (mean 6 SD) in four controls, 4 FLE, 8 HS and 10 non-HS patients showing that a subset
exhibits decreased a3-subunit staining in the superficial neocortical layers (13–18, 26–29). Sets of three immediately adjacent
sections stained for the subunits a1 (A and B), a2 (C and D) and a3 (E and F) were used. OD measurements were made in layers II
and III (A, C and E) and in layers V and VI (B, D and F) of the same section. The numbers 1–29 indicated in A refer to each of the
patients listed in Table 1. One exception is number 13 (marked with an x). In tissue from this patient, densitometric measurements
of a3-subunit staining in the superficial layers showed a lack of change in one sample and decreased staining in the other (E, xx). In contrast,
all the other densitometric measurements in this patient were uniform between blocks as reflected by the low SDs (A–D and F).
Fig. 7 Variability of a3-subunit immunoreactivity at the cellular level in the superficial neocortical layers in TLE specimens with
decreased a3-subunit staining (B–D) versus a TLE specimen with unchanged labelling (A). (A) a3-Subunit immunoreactivity showing strong
neuropil staining in layer II and weaker staining in the upper part of layer III. In (B), a3-subunit labelling is decreased throughout the
superficial layers. (C) Section showing a layer II pyramidal cell with an extensive dendritic arborization restricted to layers I and II. (D)
Section showing a large pyramidal cell also located in layer II revealed by a3-subunit immunoreactivity. Scale bar: 100 mm.
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To our knowledge, the present study provides the first
description of a3-subunit immunoreactivity in the human
neocortex, revealing a remarkably specific laminar distribu-
tion pattern. This subunit is especially interesting because, in
contrast to the other subunits, its expression differs from
that described in the rodent brain (Fritschy and Mo¨hler,
1995; Pirker et al., 2000). In rodent neocortex, a3-subunit
expression is mainly located in the deep layers, while in the
human neocortical frontal and temporal regions examined,
a3-subunit staining was also pronounced in the superficial
layers, especially in layer II. Our results further demonstrate
a cell-specific distribution of the five major GABAA
receptor subunits. The a1 together with the b2/3 and the
g2-subunits were localized not only in pyramidal cells but
also in numerous small interneurons, especially in the
superficial layers. Layer II and the upper part of layer III of
the human temporal neocortex contain smaller and a higher
density of GABA-positive somata than the other layers
(Kisva´rday et al., 1990). In contrast, the a2 and a3-subunits
were localized solely in pyramidal cells, most prominently at
the axon initial segment (Loup et al., 1998; Volk et al.,
2002).
Altered GABAA receptor subtype
expression in the grey matter of patients
with focal epilepsy
We found a selective reduction of the a3-subunit in the
neocortex of a subset of TLE patients in the absence of
a change of the a1, a2, b2/3 and g2-subunits. Data
from animal studies indicate, however, that functional
a3-containing GABAA receptors generally co-assemble with
b and g2-subunits (Sieghart and Sperk, 2002; Fritschy and
Bru¨nig, 2003). The reason that we did not detect an
associated decrease in b2/3 and g2-subunit labelling
probably relates to the ubiquitous distribution of these
subunits. The b and g2-subunits are included in the vast
majority of GABAA receptors, most frequently in combina-
tion with the a1 or a2-subunit. Thus, a decrease in the
fraction of b and g2-subunits co-expressed with the a3-
subunit, which in rodent brain constitutes only 10–20% of
the total number of GABAA receptors (Sieghart and Sperk,
2002; Fritschy and Bru¨nig, 2003), would result in a change
too low to be detected by immunohistochemical methods.
Among all known subunits the a1 is the only one
previously analysed immunohistochemically in the temporal
neocortex of patients with pharmacoresistant focal epilepsy
(Wolf et al., 1994, 1996b). In their first study where the
primary focus was the hippocampal formation, Wolf et al.
(1994) used the temporal neocortex as a reference and repor-
ted no changes in a1-subunit GABAA receptor immuno-
reactivity, which is confirmed by our data. Autoradiographic
analysis of binding at GABAA receptors or at the
benzodiazepine–GABAA receptor complex in the temporal
neocortex of patients with medically refractory focal epilepsy
has provided conflicting findings. Thus Zilles et al. (1999)
using 3H-muscimol reported a downregulation of GABAA
receptor density in four out of nine cases with non-HS and
variable upregulation in the remaining cases. In TLE patients
with HS, Olsen et al. (1992) found no significant difference
in flumazenil binding between epileptic temporal neocortex
and control tissue, whereas Burdette et al. (1995) reported a
significant increase in flumazenil binding in layers V and VI
of epileptic temporal neocortex. Taken together these studies
show non-uniform changes in GABAA receptor binding in
tissue from TLE patients. Similarly, imaging studies using
11C-flumazenil in patients with refractory focal epilepsy due
to diverse pathologies have reported not only focal decreases
but also focal increases of flumazenil binding either in
temporal or extratemporal neocortex (Theodore, 2002;
Koepp and Woermann, 2005). Until subtype-specific ligands
become available it will not be possible to determine how the
changes in a3-subunit expression observed in the present
work relate to the changes described in autoradiography and
PET studies.
In our study, the non-HS group consisted of patients with
a focal lesion located in the anterolateral temporal
neocortex. When we examined the neocortex adjacent to
the lesion, we observed that it was histologically normal in 8
of the 12 cases where we also did not find any changes in
a3-subunit staining compared to controls. In the other four
patients with decreased a3-subunit expression, we found
histopathological changes including gliosis and type IB FCD.
This type of mild MCD was present in one patient with a
DNT and one patient with a ganglioglioma. Both types of
tumours may be associated with surrounding dysplastic
cortical regions as described previously (Prayson et al., 1993;
Daumas-Duport et al., 1999; Palmini et al., 2004). Wolf et al.
(1996b) reported decreases as well as increases in a1-subunit
immunoreactivity in the perilesional tissue in a subset of
patients with neocortical lesions. We did not find alterations
in a1-subunit staining in our study, but overall these results
show that GABAA receptor changes can occur in the vicinity
of focal lesions.
The HS group comprised nine patients, three with no
change in a3-subunit labelling, five with decreased labelling
and one with a decrease in one of two tissue samples. Mild
Chaslin’s subpial gliosis was detected in two of the patients
with no change in a3-subunit labelling and in the patient
where there was reduced staining in one of the two samples.
In contrast, in four of the five cases with decreased
a3-subunit staining, we observed gliosis and/or white matter
changes, two of whom exhibited type II mild MCD (Palmini
et al., 2004). Thus, decreased a3-subunit expression in
patients with HS or with non-HS was associated in 8 out of
10 patients with histopathological changes, in particular
mild forms of MCD. We did not, however, observe neuronal
loss in TLE specimens, in agreement with previous studies
(Babb et al., 1984; Bothwell et al., 2001). These findings
suggest that the reduction in a3-subunit staining is related
primarily to a downregulation of this subunit in pyramidal
cells rather than to a loss of neurons expressing this subunit.
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Furthermore, decreased a3-subunit expression was not
accompanied by a reduction in the a1 or a2-subunits,
which would be expected were the changes a result of
extensive neuronal loss.
We also studied five patients with FLE, where we did not
find any changes in GABAA receptor subunit staining.
Whether this lack of change reflects the small sample size,
the type of pathology (absence of a circumscribed lesion
except in one case) or other factors remains unclear. It is
however interesting to note that the laminar distribution
and intensity of GABAA receptor subunits was basically
similar to that in the autopsy specimens and TLE samples.
In the patients with altered a3-subunit expression, the
laminar pattern was remarkably stereotyped with a lack of
change in deep layers and a marked decrease in staining in
superficial layers. At the cellular level it is not possible to
determine whether the more darkly stained, and therefore
visible, pyramidal cells were the last cells to express the
a3-subunit or whether these neurons expressed this subunit
de novo. Nevertheless, the selective localization in layer II
of intensely stained neurons with an extensive dendritic
arborization confined to layers I and II suggests a
reorganization of the a3-subtype in these layers. A recent
study using complementary DNA microarrays and immuno-
staining reported a pattern of persistent gene activation in
epileptic neocortex of patients with focal epilepsy mainly in
layers II and III (Rakhade et al., 2005). As the superficial
layers are primarily involved in processing activity from
other cortical areas (Jones, 1984) and electrophysiological
studies have shown the critical role of layers II and III in the
generation of synchronous population events in human
epileptic neocortex (Ko¨hling et al., 1999), downregulation of
a3-containing GABAA receptors in the superficial layers may
contribute to decreased functional inhibition.
Other GABAA receptor subunits, for which antibodies
effective in human tissue do not yet exist, might be upreg-
ulated and may thus compensate for a reduction in
a3-subunit expression. However, a recent study using
transcriptome profiling in human epileptic neocortex
reported a prominent downregulation of the a5-subunit
gene and other GABA system transcripts in both the pre-
synaptic and the post-synaptic compartments in spiking
samples (Arion et al., 2006). Further, functional and
morphological alterations in GABAergic circuits in the
neocortex of TLE patients have been described previously
(DeFelipe, 1999; Avoli et al., 2005). In particular, the group
of DeFelipe found patterns of decreased immunoreactivity
for parvalbumin (PV) and glutamate decarboxylase in
human epileptogenic neocortex (DeFelipe et al., 1993, 1994;
Marco et al., 1996). The most important change was a focal
loss of PV-positive chandelier cells (among other inter-
neurons), which are thought to be the most powerful
cortical inhibitory cells. Using quantitative electron micro-
scopy, the same group found a loss of inhibitory synapses in
the regions with marked decrease in staining for PV (Marco
and DeFelipe, 1997). Interestingly, the changes in synaptic
density in their study were most pronounced in the
superficial layers, where we observed downregulation of
a3-containing GABAA receptors. Taken together, these
results suggest a prominent reorganization of the GABAergic
circuitry, which could contribute to the genesis or the
maintenance of seizure activity in human focal epilepsy.
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